2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
LTC Properties entered into a new equity distribution agreement allowing it to sell up to $500 million of common stock at its option, through sales agents and forward sale agreements. The filing says the company terminated its prior at-the-market program, under which about $90 million remained unsold, to enter into the new agreement.
Up to $500 million of common stock may be issued and sold from time to time, at the company's option, under the agreement dated August 6, 2026.
The agreement replaces an original program dated November 13, 2024, as amended August 5, 2025, which allowed up to $400 million; about $90 million remained unsold when it was terminated.
Sales agent commissions will not exceed 2.0% of the gross sales price of shares sold through the agents.
Net proceeds may be used to pay down the unsecured revolving line of credit, fund acquisitions and originations, or for working capital and other general corporate purposes.
Procore Technologies completed a private offering of $950 million of 0% convertible senior notes due August 15, 2031, including the full $125 million option for initial purchasers. The conversion price of about $82.89 is a 50% premium over the $55.26 closing price on August 3, 2026, and the notes carry no regular interest, which adds debt but no cash coupon for the company.
Offering of $950 million principal, including the full $125 million option, closed August 6, 2026 under an indenture with U.S. Bank Trust Company as trustee
Initial conversion price of about $82.89 per share, a 50% premium over the $55.26 NYSE closing price on August 3, 2026
Company expected net proceeds of about $804.4 million before the option, or about $926.6 million with it, to fund part of the DroneDeploy cash consideration, a capped call cost of about $51.3 million, and about $175 million of share repurch
Company may not redeem the notes before August 20, 2029, except in a cleanup redemption when less than $100 million remains outstanding
Innodata entered an equity distribution agreement allowing it to sell up to $300 million of common stock through five sales agents, Goldman Sachs and four others. The company has no obligation to sell any shares and may suspend or terminate the offering at any time, and sales would dilute existing shareholders if made.
Agreement dated August 6, 2026 covers shares with an aggregate offering price of up to $300 million.
Sales agents are Goldman Sachs & Co. LLC, Craig-Hallum Capital Group LLC, Wells Fargo Securities, LLC, Maxim Group LLC, and Wedbush Securities Inc.
Sales agents receive a commission of up to 2.0% of gross proceeds from each sale.
Shares would be issued under a Form S-3 shelf registration statement (File No. 333-298075) that became effective upon filing on August 6, 2026.
Solid Biosciences filed a prospectus supplement under its existing shelf registration to offer up to $200.0 million of common stock through a sales agreement with Jefferies LLC. The company said it had already sold about $85.0 million of stock under a prior supplement, which it will no longer use once this one is filed.
Up to $200.0 million of common stock may be sold under the Amended and Restated Sales Agreement dated March 13, 2024 with Jefferies LLC.
Prior prospectus supplement covered up to $85.0 million; about $85.0 million in gross proceeds had been raised under it and the Sales Agreement as of the filing date.
Offering is made under the Form S-3 shelf registration (File No. 333-287325), declared effective May 27, 2025.
Wilmer Cutler Pickering Hale and Dorr LLP issued a legal opinion on the shares (Exhibit 5.1).
On August 6, 2026, Clearway Energy entered an equity distribution agreement allowing it to sell up to $100 million of Class C common stock through five agents over time at market prices. The company says proceeds may fund general corporate purposes, including repaying or refinancing debt, working capital, capital expenditures and acquisitions, so shareholders could see dilution if shares are sold.
Program size: up to $100,000,000 aggregate sales price of Class C common stock
Agents named: Wells Fargo Securities, Morgan Stanley, BofA Securities, Citigroup Global Markets and J.P. Morgan Securities
Shares to be issued under a prospectus supplement dated August 6, 2026, to a Form S-3 shelf registration that became effective on August 6, 2026
The filing does not state that any shares have been sold
Organogenesis entered an at-the-market sales agreement with BTIG and Citizens JMP that lets it sell Class A common stock worth up to $75 million through the agents over time. The company is not obligated to sell any shares, so any sales would depend on its instructions and would add to the number of shares outstanding.
Agreement dated August 6, 2026, with BTIG, LLC and Citizens JMP Securities, LLC as sales agents
Aggregate offering price of up to $75,000,000 under a prospectus supplement dated August 6, 2026
Agents receive a commission of up to 3.0% of gross sales price per share sold
Shares are offered under a Form S-3 shelf registration effective August 15, 2024; the company has no obligation to sell
TCGX Acquisition Corp., a special purpose acquisition company focused on healthcare, closed its initial public offering on August 6, 2026, selling 8,625,000 Class A ordinary shares at $10.00 each for gross proceeds of $86.25 million. The filing says $86.25 million was placed in a trust account, which will not be released except for a business combination, certain shareholder redemptions, or interest used for taxes, and the company has 24 months from the IPO closing to complete a business combination. Three independent directors were appointed and two directors resigned.
Sold 8,625,000 Class A ordinary shares at $10.00 per share, including 1,125,000 shares from the full exercise of the underwriters' over-allotment option, for gross proceeds of $86.25 million.
Concurrent private placement of 522,500 shares at $10.00 per share, or $5.225 million, to the sponsor (436,250 shares) and Jefferies LLC (86,250 shares).
$86.25 million placed in a trust account at Citibank, N.A., with a 24-month deadline from the IPO closing to complete an initial business combination.
Andrew Cheng, Ying Huang and Wei Lin appointed to the board on August 4, 2026; Chen Yu and Craig Skaling resigned from the board.
Silvaco Group issued a $10.0 million unsecured senior convertible note to Micron Technology, a customer, after signing a purchase agreement on August 5, 2026 and closing on August 6, 2026. The note bears 8.0% simple interest and automatically converts into common stock on August 7, 2028 or before a change of control, so it may dilute existing shareholders by an amount that cannot yet be determined.
Principal of $10.0 million, 8.0% simple interest per annum, unsecured
Automatic conversion on August 7, 2028, or before a change of control, at the lower of 90% of fair market value or 115% of the prior closing price
Conversion shares capped by Nasdaq Listing Rule 5635(d) limit; if stockholder approval is not obtained, Silvaco must make a cash payment to Micron
While the note is outstanding, Silvaco may incur up to $50.0 million of additional subordinated borrowings
VICI Properties' operating partnership agreed to sell $900 million of 5.400% notes due 2031 and $850 million of 5.750% notes due 2036, with closing expected August 14, 2026. The company estimates net proceeds of about $1,720.0 million, which it plans to use mainly to repay several 2026 maturities, including $1.25 billion of 4.250% notes due December 2026.
Offering totals $1.75 billion: $900 million of 5.400% notes due October 15, 2031 issued at 99.966% of par and $850 million of 5.750% notes due October 15, 2036 issued at 98.375% of par
Estimated net proceeds of about $1,720.0 million, with closing expected August 14, 2026
Proceeds earmarked to repay $480.5 million of 4.500% notes due 2026, $19.5 million of 4.500% MGP notes due 2026 and $1.25 billion of 4.250% notes due December 2026, with any remainder for general corporate purposes
Beachbody entered into Amendment No. 2 to its credit agreement with Tiger Finance, LLC on August 3, 2026. The amendment drops the billings fixed charge coverage ratio covenant and lowers the minimum cash threshold to $22.5 million, but raises the minimum liquidity level from $15 million to $18 million and removes a step-down that would have set the interest rate at SOFR plus 7.75%, so the rate is now SOFR plus 9.00% until maturity.
Amendment No. 2 to Credit Agreement dated August 3, 2026, with Tiger Finance, LLC as administrative and collateral agent
Billings fixed charge coverage ratio covenant eliminated; minimum cash threshold reduced to $22.5 million
Minimum liquidity increased from $15 million to $18 million, decreasing by about $162,000 monthly from March 1, 2027, to $16 million
Interest rate is SOFR plus 9.00%, with the SOFR plus 7.75% step-down removed
Grace Therapeutics sold 4,761,904 shares of common stock at $2.10 per share in a private placement to institutional and accredited investors, for approximately $10 million in gross proceeds before placement agent fees and expenses. The offering closed on August 6, 2026. The company expects the proceeds, with existing cash, to extend its cash runway to the end of calendar 2028, but the new shares add to the outstanding share count and the company has agreed to register them for resale.
4,761,904 shares sold at $2.10 per share, for approximately $10 million in gross proceeds
Offering closed August 6, 2026; Craig-Hallum Capital Group LLC acted as placement agent
Company expects cash runway to extend to the end of calendar 2028; proceeds will support manufacturing and regulatory work for GTx-104
Company agreed to register the resale of the shares and generally may not issue more shares or file a registration statement for 90 days after closing, subject to exceptions
Quanta Services issued $2.0 billion of senior unsecured notes on August 6, 2026, in three tranches maturing in 2029, 2033 and 2036, sold under an August 3, 2026 underwriting agreement. The filing adds $2.0 billion of debt to the company's obligations, and the notes are not guaranteed by its subsidiaries, so shareholders should note that their claims rank behind subsidiary creditors.
$500 million of 4.850% Senior Notes due August 9, 2029
$750 million of 5.300% Senior Notes due August 9, 2033
$750 million of 5.550% Senior Notes due August 9, 2036; interest on all three series is payable semi-annually, starting February 9, 2027
Scholar Rock Holding Corporation filed a prospectus supplement for an at-the-market offering that lets it sell up to $200 million of common stock through Jefferies as sales agent, at its discretion. The filing replaces the prior supplement dated November 14, 2025, whose offering has been terminated, and the company says it has raised about $257.7 million in net proceeds under the ATM Program to date. New share sales would add to existing shareholders' ownership and could dilute their stake.
Up to $200,000,000 in additional common stock may be sold through Jefferies, filed August 6, 2026
Replaces the prospectus supplement dated November 14, 2025, which has been terminated
About $257.7 million in net proceeds raised under the ATM Program to date
Shares are registered under a Form S-3ASR shelf filed October 7, 2024
CG Oncology reported a second-quarter 2026 net loss of $79.1 million, or $(0.90) per share, up from $41.4 million, or $(0.54), a year earlier, on revenue of $1.2 million. The company also filed an amendment to increase by $500.0 million the shares it can sell under its Jefferies at-the-market sale agreement, which could add to dilution for existing shareholders.
Q2 2026 net loss was $79.1 million, or $(0.90) per share, versus $41.4 million, or $(0.54) per share, in Q2 2025.
Research and development expenses were $54.7 million, compared with $31.3 million a year earlier.
Cash, cash equivalents and marketable securities were $1.0 billion as of June 30, 2026, down from $1.1 billion as of March 31, 2026.
Amendment No. 2 adds $500.0 million of shares available under the Jefferies sale agreement dated March 28, 2025, after about $550.0 million was previously sold.
Karman Holdings entered into a Fifth Amendment to its credit agreement with Citibank, N.A. as administrative agent, dated August 3, 2026. The amendment refinanced $763,961,000 of existing term loans at a rate 50 basis points lower, now SOFR plus 2.25%, and lowered the revolving credit facility rates by 50 basis points at each leverage level.
Term loans refinanced in an aggregate principal amount of $763,961,000
Term loan rate reduced 50 basis points to SOFR plus 2.25%
Revolving credit facility rates cut 50 basis points at each leverage level; highest level now SOFR plus 2.00%
Other credit agreement terms remain unchanged, per the filing
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.